Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · December 01, 2024

Adding Talazoparib to Atezolizumab Maintenance Therapy for SLFN11-Positive Extensive-Stage SCLC

Journal of Thoracic Oncology

 

Additional Info

Journal of Thoracic Oncology
Phase II randomized study of maintenance atezolizumab (A) versus atezolizumab + talazoparib (AT) in patients with SLFN11 positive extensive stage small cell lung cancer. S1929
J Thorac Oncol 2024 Nov 04;[EPub Ahead of Print], NA Karim, J Miao, KL Reckamp, CM Gay, LA Byers, YQ Zhao, MW Redman, DR Carrizosa, WL Wang, WJ Petty, K Mehta, BA Faller, ES Agamah, SS Kasbari, RK Malisetti, A Kumar, J Schallenkamp, KC Alluri, JE Gray, K Kelly

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading